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Abstract
Background: Prostate cancer is the sixth leading cause of death from cancer among men worldwide. We have
previously reported that prostate cancer survival rates for Caribbean-born males in the US was similar to survival
rates of African-Americans and was higher than their counterparts diagnosed in the Caribbean. However, it is not
clear whether differences in mortality could be attributed to differences in treatment.
Methods: This current analysis seeks to further explore reasons for the geographic variation of prostate cancer
survival for Caribbean-born men. This analysis included 2,554 Black newly diagnosed prostate cancer cases (960
cases diagnosed in the US and 1,594 cases diagnosed in the Caribbean). Clinical data were extracted from the
cancer registry and clinical charts.
Results: There were noted differences in the pattern of treatment for each place of birth category when stratified
according to disease stage at diagnosis. Among the patients diagnosed with early-intermediate disease (stage I-III)
the majority of US-born Brooklyn men were treated with surgery only (31%) and a similar pattern was observed for
Caribbean-born Brooklyn men (35%). In contrast, the majority of Caribbean-born Trinidad & Tobago men were
treated with hormone therapy (31%).
Caribbean-born men diagnosed in the Caribbean had a significantly higher risk of death from prostate cancer
(Adjusted Hazard [AdjHR]: 3.7, 95% Confidence Interval [CI]: 2.8-5.0) when compared with the risk of death for
Caribbean-born males diagnosed in the US. This observation was consistent for each treatment group with the
exception of the cases treated with hormone therapy only. For these cases, there was no difference in the risk of
death between Caribbean-born males diagnosed in the Caribbean (AdjHR: 1.4, 95% CI: 0.8-2.6) compared to
Caribbean-born males diagnosed in the US.
Conclusions: In addition to difference in access and utilization of screening, differences in treatment strategy may
also be a strong predictor of outcome for Caribbean-born males diagnosed with prostate cancer. Further studies
are needed to confirm these findings. In addition, other environmental factors related to survival that was not
considered in this analysis also need to be investigated.
Background
Prostate cancer is the sixth leading cause of death from
cancer among men worldwide [1]. The age-adjusted
death rates are highest in black populations within the
United States (US) (52.0 per 100,000 in 2007) [2], and in
other geographic regions such as the Caribbean (26.3 per
100,000 in 2008) and Sub-Saharan Africa (18.5 per
100,000 in 2008) [1]. In a previously published study,
cancer registry data from the US (Brooklyn) and the
Caribbean (Trinidad & Tobago and Guyana) were evalu-
ated to determine the contribution of place of birth to
prostate cancer survival rates among black men [3]. We
reported after adjusting for age and stage at diagnosis
that survival rates were lower for Black men diagnosed in
the Caribbean compared to black men diagnosed in the
US and that Caribbean-born males diagnosed in the US
* Correspondence: camilleragin@gmail.com
1Cancer Prevention and Control Program, Fox Chase Cancer Center,
Philadelphia, Pennsylvania, USA
Full list of author information is available at the end of the article
Ragin et al. Infectious Agents and Cancer 2011, 6(Suppl 2):S2
http://www.infectagentscancer.com/content/6/S2/S2
© 2011 Ragin et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.had similar survival rates as African-Americans. It is
possible that the difference in outcome between these
two groups of Caribbean-born men may be explained by
higher utilization of screening and/or easier access to
care and to efficacious treatment in the US. This current
analysis seeks to further explore the geographic variation
of prostate cancer survival for Caribbean men in order to
shed some insight on the previous findings and to con-
firm this hypothesis. Further explorations were made to
determine whether the geographic variation of prostate
cancer survival for Caribbean-born men may be attribu-
ted to differences in treatment strategy.
Methods
De-identified cancer registry datasets were obtained for
all men diagnosed with histologically confirmed prostate
cancer between 1995 and 2007 from the US (all cases
diagnosed and/or treated at the University Hospital of
Brooklyn, Brooklyn, New York, USA) and Caribbean (all
cases diagnosed and treated in Trinidad & Tobago).
Detailed methods related to data collection and coding
were previously described [3]. The cancer registry study
population (N = 5,533) consisted of 1,100 males diag-
nosed and/or treated in the US and 4,433 males diag-
nosed and treated in the Caribbean (Trinidad & Tobago).
This current analysis was limited to Black males only (N
= 3,424). Among these, 662 cases (19%) diagnosed in the
Caribbean and 392 cases (11%) diagnosed in the US were
excluded because place of birth was not specified and
208 cases (6%) diagnosed in the Caribbean were excluded
because treatment data were not available. Therefore the
final number of cases included in this analysis was 2,162
prostate cancer cases (568 cases diagnosed in the US and
1,594 cases diagnosed in the Caribbean).
Statistical analyses were performed using STATA SE
(version 10.1) software (StataCorp. LP, College Station,
TX, USA). Place of birth for all cases was classified as
US-born Brooklyn, Caribbean-born Brooklyn, African-
born Brooklyn and Caribbean-Born Trinidad & Tobago.
Marital status was categorized as single, married (includ-
ing common-law marriage) and other (which includes
separated, divorced and widowed). For comparison
between cancer registry datasets, stage at diagnosis was
reclassified as Stage I-III (localized or regional) and Stage
IV (distant). Treatment was categorized as having no
treatment (i.e. no surgery, radiotherapy or hormone ther-
apy), surgery only, radiotherapy only, hormone therapy
only or combination therapy (surgery and/or radiother-
apy and/or hormone therapy). Follow up time was calcu-
lated in months by subtracting the date of diagnosis from
the date of last contact (for cases that were alive) or from
the date of expiration (for cases that were dead). All sta-
tistical tests were two-sided, and a P-value less than 0.05
were considered statistically significant.
One-way analysis of variance was performed in order
to compare the differences in mean age across cate-
gories of place of birth. Associations between place of
birth and stage at diagnosis or treatment were analyzed
using the chi-square test. Multivariable cox proportional
hazard models estimated the risk of death for each place
of birth category according to the type of treatment
received.
Results
Stage at diagnosis and treatment according to place of
birth
The majority of the cases were married and there were
no significant differences according to place of birth. The
mean age at diagnosis was similar for men diagnosed in
the US irrespective of their place of birth (US-born
Brooklyn men: 65.1 years, standard deviation [SD] ± 9.7;
Caribbean-born Brooklyn men: 66.2 years, SD ± 8.5 and
African-born Brooklyn men: 64.6 ± 9.8) while the mean
age at diagnosis for Caribbean-born men in Trinidad &
Tobago were significantly higher than men diagnosed in
the US (70.4 years, SD ± 9.5) (test of equal variance, p –
value: 0.044). For both the US and Trinidad & Tobago
males, adenocarcinoma was the most common histologic
type that was diagnosed. The majority of cases were diag-
nosed at stage I-III irrespectively of their place of birth
(Table 1). However, twenty-one percent of Caribbean-
born males diagnosed in Trinidad and Tobago had
advanced disease (stage IV) while the proportion of stage
IV disease among males diagnosed in Brooklyn varied
from 7% for Caribbean born men living in the US to 10%
for US born men . Further stratification of the cases diag-
nosed in Trinidad & Tobago revealed that the proportion
of early-intermediate stage and late-stage cancers were
different between the two islands. For Tobago, 75% of
the cases were diagnosed with early-intermediate stage
disease and 11% diagnosed with late stage disease, 14% of
the cases were not staged. In contrast, 56% of the cases in
Trinidad were diagnosed with early-intermediate disease,
24% were diagnosed with late stage disease and 20% were
not staged.
Among the patients diagnosed with early-intermediate
disease (stage I-III) the majority of US-born Brooklyn
men were treated with surge r yo n l y( 3 1 % )a n das i m i l a r
pattern was observed for Caribbean-born Brooklyn men
(35%) as well as for Africa-born Brooklyn men (31%). In
contrast, the majority of Caribbean-born Trinidad &
Tobago men were treated with hormone therapy (31%).
For patients diagnosed with advanced disease (Stage IV)
the majority of US-born Brooklyn men had no treatment
(50%). In contrast to US-born men diagnosed in Brooklyn,
the pattern of treatment appeared to be similar for Carib-
bean-born Brooklyn men and Caribbean-born Trinidad &
Tobago men. A fairly close to equal proportion of patients
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combination therapy was observed for these groups.
Survival rates and place of birth according to stage at
diagnosis and treatment received
Overall survival rates for each place of birth category stra-
tified according to stage at diagnosis revealed differences
in outcome for Caribbean men. For cases diagnosed with
early/intermediate stage cancer, the five-year survival rates
for men diagnosed in Brooklyn were about two-fold higher
than that of Caribbean-born men diagnosed in Trinidad &
Tobago men, this was irrespective of whether the Brooklyn
men were born in the US, Caribbean or Africa (84%, 82%
and 77% vs. 41%). In contrast, for the cases diagnosed with
advanced disease the 5-year survival rate for US-born men
diagnosed in Brooklyn was 49%, while much lower but
similar five-year survival rates were seen for Caribbean-
born men diagnosed in Brooklyn and Caribbean-born
men diagnosed in Trinidad & Tobago (29% and 10%
respectively).
Table 2 summarizes the hazard ratios for each place of
birth category according to the type of treatment after
adjusting for stage and age at diagnosis. For the overall
study population, and as previously reported [3], Carib-
bean-born men diagnosed in the Caribbean had a signifi-
cantly higher risk of death from prostate cancer (Adjusted
Hazard [AdjHR]: 3.8, 95% Confidence Interval [CI]: 2.8-
5.1) when compared with the risk of death for Caribbean-
born males diagnosed in the US. This observation was
consistent for each treatment group with the exception of
the cases treated with hormone therapy only. For these
cases, there was no difference in the risk of death between
Caribbean-born males diagnosed in the Caribbean
(AdjHR: 1.4, 95% CI: 0.8-2.6) compared to Caribbean-born
males diagnosed in the US. In contrast, the African-born
men treated with hormone therapy only were shown to
have a significantly increased risk of death compared to
the Caribbean-born Brooklyn men. For all other treatment
groups, there was no difference in the risk of death
between African-born and Caribbean-born men diagnosed
in the US. It was not possible to determine the risk of
death for US-born males diagnosed in the US because
only two cases treated with hormone therapy only. Simi-
larly, the risk of death for African-born males diagnosed in
the US and treated with combination therapy could not be
estimated because there were too few cases.
Table 1 Clinical and treatment characteristics of prostate cancer cases
Characteristic US-born Brooklyn
N = 125
N (%)
African-born Brooklyn
N=3 7
N (%)
Caribbean-born Brooklyn
N = 406
N (%)
Caribbean-born Trinidad &Tobago
N = 1,594
N (%)
P-Value
Histology
Carcinoma, NOS 4 (3.2) 2 (5.4) 5 (1.2) 177 (11.1) <0.0001
Adenocarcinoma 121 (96.8) 35 (94.6) 397 (97.8) 1,406 (88.2)
Other
1 0 (0.0) 0 (0.0) 4 (0.99) 11 (0.7)
Stage
I-III 111 (88.8) 32 (86.5) 367 (90.4) 953 (59.8) <0.0001
IV 12 (9.6) 3 (8.1) 27 (6.7) 338 (21.2)
Unstaged 2 (1.6) 2 (5.4) 12 (3.0) 303(19.0)
Treatment
Stage I-III N = 111 N = 32 N = 367 N = 953 <0.0001
No treatment 32 (28.8) 9 (28.1) 54 (14.7) 250 (26.2)
Surgery only 34 (30.6) 10 (31.2) 128 (34.9) 107 (11.2)
Radiotherapy only 29 (26.1) 5 (15.6) 83 (22.6) 64 (6.7)
Hormone therapy only 0 (0.0) 0 (0.0) 13 (3.5) 295 (31.0)
Combination therapy* 16 (14.4) 8 (25.0) 89 (24.3) 237 (24.9)
Treatment
Stage IV N = 12 N = 3 N = 27 N = 338 0.295
No treatment 6 (50.0) 1 (33.3) 9 (33.3) 124 (36.7)
Surgery only 2 (16.7) 0 (0.0) 1 (3.7) 13 (3.9)
Radiotherapy only 2 (16.7) 1 (33.3) 2 (7.4) 32 (9.5)
Hormone therapy only 2 (16.7) 1 (33.3) 9 (33.3) 74 (21.9)
Combination therapy* 0 (0.0) 0 (0.0) 6 (22.2) 95 (28.1)
*Combination refers to any combination of surgery, radiation and hormone therapy or at least two different types of therapy.
1Other (histology): Glandular
intraepithelial neoplasia, grade III; Small cell carcinoma; Squamous cell carcinoma; Transitional cell carcinoma; Cribriform carcinoma; Acinar cell carcinoma and
Sarcoma.
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Geographic and outcome variation of prostate cancer sur-
vival has been well documented [4]. In this analysis, our
aim was to further explore the geographic and outcome
variation for prostate cancer for black Caribbean males.
Using cancer registry data, we have evaluated whether dif-
ferences in treatment may account for the observed differ-
ence on outcome for Caribbean-born males diagnosed in
the US compared to those diagnosed in the Caribbean. In
this as well as a previous study, we have shown that Carib-
bean-born males diagnosed in the US have survival benefit
over Caribbean-born males diagnosed in the Caribbean
[3]. Possible explanations for this finding may be related to
improved access to screening and medical care. We antici-
pate that a population with adequate access and utilization
of screening would subsequently have a higher proportion
of cases diagnosed early. This analysis highlights that the
majority of cases in the US were diagnosed at stage I-III
while Caribbean-born cases diagnosed in the Caribbean
were diagnosed mostly with advance stage disease thus
supporting the notion that access to screening is likely to
contribute to the geographic variation in survival for Black
Caribbean-born men. Further stratification of the cases
diagnosed in Trinidad & Tobago revealed a much smaller
proportion of late stage cancers diagnosed in Tobago
(11%), which was similar to that of US men (range accord-
ing to place of birth, 7-10%) compared to 24% of men
diagnosed with late stage cancers in Trinidad. For more
than a decade, a longitudinal prostate cancer screening
study has been conducted in Tobago and a high preva-
lence of screening-detected prostate cancer cases has been
reported [5]. This may help to explain why there is a
higher proportion of early-intermediate stage disease diag-
nosed in Tobago compared to Trinidad and demonstrates
the impact of screening on prostate cancer stage at
diagnosis.
In addition to access and utilization of screening, dif-
ferences in treatment strategy may also be a strong pre-
dictor of outcome for Caribbean-born males diagnosed
with prostate cancer. Treatment patterns between cases
diagnosed with early-intermediate and advanced disease
were different. Furthermore, the pattern of treatment
correlated with outcome. For early-intermediate stage
disease, Caribbean-born males diagnosed in the US had
similar treatment patterns as US-born males and both
groups showed similar 5-year survival rates (84% vs
82%). In contrast, for cases with late-stage disease, Car-
ibbean-born males diagnosed in the US had dissimilar
t r e a t m e n tp a t t e r n sa sU S - b o r nm a l e sa n dw e r em o r e
closely related to their counterparts diagnosed in the
Caribbean. Both Caribbean-born groups had similar 5-
year survival rates.
In general the Caribbean islands are considered devel-
oping nations with limited resources; therefore it would
not be unusual to assume that there may be limited
resources available for adequate cancer care. Our analysis
includes data for cases diagnosed in the Caribbean nation
of Trinidad & Tobago which unlike most Caribbean
islands, has a high-income economy according to the
World Bank classification [6] and PSA and DRE screen-
ing is available through a public universal health care sys-
t e mp r o v i d e dt ot h eg e n e r a lp u b l i c .T h e r e f o r e ,i ti s
possible that there may not be as large a disparity in the
available resources for cancer treatment compared to the
US as it may be for other Caribbean nations. It is impor-
tant to note that when the cases were stratified according
to treatment received, for those cases treated with hor-
mone therapy, there was no difference in outcome
between Caribbean-born males diagnosed in the US
compared to Trinidad & Tobago. For Caribbean-born
males treated in the US, hormone therapy appears to be
the more common treatment approach only for advanced
disease which is in contrast to their Caribbean counter-
parts since hormone therapy is more commonly used
irrespective of cancer stage. Our findings suggest that
treatment might be a strong predictor of outcome for
Caribbean-born males. Further studies of the geographic
variation of prostate cancer outcome for Caribbean-born
Table 2 Risk of death among Black men according to type of treatment received
No treatment
N = 493
Surgery only
N = 310
Radiotherapy
only
N = 236
Hormone therapy
only
N = 449
Combination
therapy
N = 630
Place of Birth/registry AdjHR (95% CI)
**
AdjHR (95% CI)
**
AdjHR (95% CI)
** AdjHR (95% CI)
** AdjHR (95% CI)
**
Caribbean-born Brooklyn Reference Reference Reference Reference Reference
US-born Brooklyn 0.9
(0.3-2.9)
0.6
(0.1-3.2)
1.4
(0.6-3.4)
– 1.1
(0.3-4.0)
Caribbean-born Trinidad &
Tobago
4.4
(2.3-8.5)
3.9
(1.7-9.1)
3.0
(1.3-7.1)
1.4
(0.8-2.6)
5.2
(2.9-9.3)
African-born Brooklyn 2.2
(0.5 –10.1)
2.8
(0.3-23.7)
3.3
(0.7-15.0)
6.2
(1.4-28.4)
–
AdjHR = Hazard ratio; *After adjusting for treatment and age at diagnosis and stage –
**adjusting for age and stage
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gies and other environmental factors related to survival
that were not considered in this analysis.
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